Company: NGVT
Filing Date: 2025-03-10
Form Type: DEFA14A
Source: 0001140361-25-007877
Chunk: 4

Company: Ingevity Corp
Filing Date: 2025-03-10
Form: DEFA14A
Chunk 4
---
 within Ingevity and position the company for long-term profitable growth and superior value creation.” – DAVID LI ~16% cumulative annual revenue growth1 RECORD $1.2B of revenues2 +1,750 issued and pending patents2 30% adjusted EBITDA margin2 ~14% cumulative annual operating profit growth1 $6.5B sale to Entegris — 35% premium3 ~$2B of acquisitions, expanding into electronic materials and performance solutions ~300% total shareholder returns compared to ~78% for S&P 4004 Career Highlights President & CEO2015 – 2022 Vice President, Asia Pacific Region 2008 – 2014 Various senior leadership roles in product line management, operations, supply chain, IR 1998 – 2008 Education BS MBA 1. From Fiscal Year 2014 to Q2 Fiscal Year 2022 LTM 2. Fiscal Year 2021 (LTM at the time of the announced sale to Entegris on Dec 15, 2021) 3. Premium at announcement over CMC Materials closing stock price as of Dec 14, 2021, day before announcement of Entegris acquisition 4. From appointment on Jan 1, 2015 to Jul 5, 2022, the last trading day prior to the close of sale to Entegri

Additional Information and Where to Find It: In connection with Ingevity’s 2025 annual meeting of stockholders (the “2025 Annual Meeting”), Ingevity filed on March 10, 2025 with the Securities and Exchange Commission (“SEC”) a preliminary proxy statement on Schedule 14A (the “Proxy Statement”), containing a form of WHITE proxy card. The Proxy Statement is in preliminary form and Ingevity intends to file and mail to stockholders of record entitled to vote at the 2025 Annual Meeting a definitive proxy statement and other documents, including a WHITE proxy card. This communication is not a substitute for any proxy statement or other document that Ingevity has filed or may file with the SEC in connection with any solicitation by Ingevity. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) FILED BY INGEVITY AND ALL OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENT